Income Statement (TTM)
Adverum Biotechnologies, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 8 | 8 | 8 | 8 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 0 | 0 | 1 | 1 | 1 | 1 |
| Change (%) | ∞ | 0.00 | 0.00 | 0.00 | -100.00 | NaN | NaN | ∞ | 0.00 | 0.00 | 0.00 | -100.00 | NaN | ∞ | 0.00 | 0.00 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||||||
| Cost Of Sales | 62 | 79 | 82 | 88 | 89 | 92 | 98 | 99 | 94 | 86 | 83 | 77 | 72 | 68 | 68 | 77 | 90 | 110 |
| Change (%) | 26.77 | 4.37 | 7.74 | 0.98 | 3.35 | 6.13 | 0.87 | -5.06 | -8.17 | -3.61 | -6.54 | -7.29 | -4.87 | -0.44 | 13.24 | 17.31 | 22.16 | |
| % of Revenue | 1,047.17 | 1,092.92 | 1,177.51 | 1,189.08 | 2,602.00 | 2,389.36 | 2,303.00 | 2,152.39 | 6,803.40 | 7,704.10 | 9,037.80 | 11,040.60 | ||||||
| Gross Operating Profit | -62 | -71 | -74 | -81 | -82 | -92 | -98 | -99 | -90 | -82 | -79 | -74 | -72 | -68 | -67 | -76 | -89 | -109 |
| Change (%) | 14.66 | 4.83 | 8.52 | 1.07 | 12.84 | 6.13 | 0.87 | -8.71 | -8.50 | -3.77 | -6.84 | -2.77 | -4.87 | -1.90 | 13.44 | 17.54 | 22.41 | |
| % of Revenue | -947.17 | -992.92 | -1,077.51 | -1,089.08 | -2,502.00 | -2,289.36 | -2,203.00 | -2,052.39 | -6,703.40 | -7,604.10 | -8,937.80 | -10,940.60 | ||||||
| SG&A | 39 | 52 | 63 | 66 | 63 | 62 | 54 | 57 | 52 | 51 | 48 | 55 | 56 | 59 | 55 | 63 | 69 | 66 |
| Change (%) | 31.82 | 21.89 | 4.92 | -4.26 | -1.57 | -13.10 | 5.04 | -8.08 | -2.47 | -6.66 | 15.54 | 1.83 | 5.96 | -6.75 | 13.93 | 9.01 | -4.47 | |
| % of Revenue | 690.19 | 841.28 | 882.64 | 845.04 | 1,454.03 | 1,418.08 | 1,323.67 | 1,529.33 | 5,539.90 | 6,311.80 | 6,880.30 | 6,572.60 | ||||||
| R&D | ||||||||||||||||||
| Change (%) | ||||||||||||||||||
| % of Revenue | ||||||||||||||||||
| OpEx | 101 | 130 | 145 | 155 | 153 | 155 | 152 | 156 | 146 | 137 | 131 | 133 | 128 | 128 | 123 | 140 | 159 | 176 |
| Change (%) | 28.73 | 11.33 | 6.51 | -1.26 | 1.30 | -1.63 | 2.36 | -6.17 | -6.13 | -4.75 | 1.52 | -3.50 | -0.13 | -3.37 | 13.55 | 13.57 | 10.65 | |
| % of Revenue | 1,737.36 | 1,934.20 | 2,060.15 | 2,034.12 | 4,056.03 | 3,807.44 | 3,626.67 | 3,681.72 | 12,343.30 | 14,015.90 | 15,918.10 | 17,613.20 | ||||||
| Operating Income | -101 | -123 | -138 | -147 | -145 | -155 | -152 | -156 | -142 | -133 | -127 | -129 | -128 | -128 | -122 | -139 | -158 | -175 |
| Change (%) | 21.32 | 12.02 | 6.87 | -1.33 | 6.54 | -1.63 | 2.36 | -8.48 | -6.28 | -4.88 | 1.56 | -0.81 | -0.13 | -4.16 | 13.66 | 13.67 | 10.72 | |
| % of Revenue | -1,637.36 | -1,834.20 | -1,960.15 | -1,934.12 | -3,956.03 | -3,707.44 | -3,526.67 | -3,581.72 | -12,243.30 | -13,915.90 | -15,818.10 | -17,513.20 | ||||||
| Interest Expense | ||||||||||||||||||
| Change (%) | ||||||||||||||||||
| % of Revenue | ||||||||||||||||||
| Net Income | -99 | -123 | -138 | -149 | -146 | -155 | -154 | -156 | -146 | -133 | -126 | -122 | -120 | -119 | -113 | -131 | -151 | -169 |
| Change (%) | 24.53 | 12.30 | 7.67 | -2.17 | 6.51 | -0.37 | 1.15 | -6.74 | -8.41 | -5.43 | -3.23 | -1.56 | -0.84 | -4.82 | 15.41 | 15.18 | 12.40 | |
| % of Revenue | -1,640.49 | -1,842.27 | -1,983.51 | -1,940.53 | -4,046.78 | -3,706.47 | -3,505.19 | -3,392.11 | -11,344.40 | -13,092.70 | -15,079.90 | -16,949.20 | ||||||
Source: Capital IQ
